Data source,Date of update,Product name,Product type,Non-traditionals categories,Antibacterial class,Indications,Route of administration,R&D phase,Developer,Pathogen category,Pathogen name,Pathogen activity,Active against priority pathogens?,Innovative?,NCE?,Mycobacterium tuberculosis,Clostridioides difficile
WHO AMR pipeline analysis,Nov-21,Bacteriophage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,"Tashkent Pediatric Medical
Institute",Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Bacteriophage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,"Tashkent Pediatric Medical
Institute",Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Bacteriophage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,"Tashkent Pediatric Medical
Institute",Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Bacteriophage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,"Tashkent Pediatric Medical
Institute",Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Bacteriophage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,"Tashkent Pediatric Medical
Institute",Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Bacteriophage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,"Tashkent Pediatric Medical
Institute",Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Bacteriophage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,"Tashkent Pediatric Medical
Institute",Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Bacteriophage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,"Tashkent Pediatric Medical
Institute",Priority pathogens,Enterococcus faecium,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Bacteriophage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,"Tashkent Pediatric Medical
Institute",Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Bacteriophage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,"Tashkent Pediatric Medical
Institute",Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Bacteriophage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,"Tashkent Pediatric Medical
Institute",Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Bacteriophage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,"Tashkent Pediatric Medical
Institute",Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Bacteriophage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,Gram positive and Gram negative,Inhalation,Phase III,"Tashkent Pediatric Medical
Institute",Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,9MW1411,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,Mabwell Bioscience,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,9MW1411,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,Mabwell Bioscience,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,9MW1411,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,Mabwell Bioscience,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,9MW1411,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,Mabwell Bioscience,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,9MW1411,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,Mabwell Bioscience,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,9MW1411,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,Mabwell Bioscience,Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,9MW1411,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,Mabwell Bioscience,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,9MW1411,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,Mabwell Bioscience,Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,9MW1411,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,Mabwell Bioscience,Priority pathogens,Enterobacterales,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,9MW1411,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,Mabwell Bioscience,Priority pathogens,Critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,9MW1411,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,Mabwell Bioscience,Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,9MW1411,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,Mabwell Bioscience,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,9MW1411,Non-traditional,Antibodies,Monoclonal antibody,S. aureus,IV,Phase I,Mabwell Bioscience,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AB103,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,Atox Bio,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AB103,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,Atox Bio,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,AB103,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,Atox Bio,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AB103,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,Atox Bio,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,AB103,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,Atox Bio,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AB103,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,Atox Bio,Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AB103,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,Atox Bio,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,AB103,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,Atox Bio,Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AB103,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,Atox Bio,Priority pathogens,Enterobacterales,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AB103,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,Atox Bio,Priority pathogens,Critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AB103,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,Atox Bio,Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AB103,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,Atox Bio,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AB103,Non-traditional,Immunomodulating agents,Antagonist of superantigen exotoxins and CD28 T-cell,"S. aureus necrotizing soft tissue infection, acute kidney injury, peritonitis",IV,Preregistration,Atox Bio,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Afabicin,Antibiotics,,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,Debiopharm International SA,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Afabicin,Antibiotics,,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,Debiopharm International SA,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Afabicin,Antibiotics,,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,Debiopharm International SA,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Afabicin,Antibiotics,,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,Debiopharm International SA,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Afabicin,Antibiotics,,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,Debiopharm International SA,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Afabicin,Antibiotics,,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,Debiopharm International SA,Priority pathogens,Helicobacter pylori,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Afabicin,Antibiotics,,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,Debiopharm International SA,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Afabicin,Antibiotics,,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,Debiopharm International SA,Priority pathogens,Enterococcus faecium,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Afabicin,Antibiotics,,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,Debiopharm International SA,Priority pathogens,Enterobacterales,Critical priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Afabicin,Antibiotics,,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,Debiopharm International SA,Priority pathogens,Critical priority pathogens,Critical priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Afabicin,Antibiotics,,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,Debiopharm International SA,Priority pathogens,Campylobacter spp.,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Afabicin,Antibiotics,,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,Debiopharm International SA,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Afabicin,Antibiotics,,FabI inhibitor,"ABSSI (caused by S. aureus), osteomyelitis","IV, Oral",Phase II,Debiopharm International SA,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,ALS-4,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Aptorum Group,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,ALS-4,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Aptorum Group,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,ALS-4,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Aptorum Group,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,ALS-4,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Aptorum Group,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,ALS-4,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Aptorum Group,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,ALS-4,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Aptorum Group,Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,ALS-4,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Aptorum Group,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,ALS-4,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Aptorum Group,Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,ALS-4,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Aptorum Group,Priority pathogens,Enterobacterales,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,ALS-4,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Aptorum Group,Priority pathogens,Critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,ALS-4,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Aptorum Group,Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,ALS-4,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Aptorum Group,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,ALS-4,Non-traditional,Miscellaneous,Staphyloxanthin biosynthesis inhibition,S. aureus,Oral,Phase I,Aptorum Group,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AP-PA02,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Armata Pharmaceuticals,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AP-PA02,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Armata Pharmaceuticals,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AP-PA02,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Armata Pharmaceuticals,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,AP-PA02,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Armata Pharmaceuticals,Priority pathogens,Other priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AP-PA02,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Armata Pharmaceuticals,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AP-PA02,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Armata Pharmaceuticals,Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AP-PA02,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Armata Pharmaceuticals,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AP-PA02,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Armata Pharmaceuticals,Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AP-PA02,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Armata Pharmaceuticals,Priority pathogens,Enterobacterales,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AP-PA02,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Armata Pharmaceuticals,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,AP-PA02,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Armata Pharmaceuticals,Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AP-PA02,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Armata Pharmaceuticals,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AP-PA02,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Armata Pharmaceuticals,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-301,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-301,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-301,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-301,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Other priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-301,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-301,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-301,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-301,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-301,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Enterobacterales,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-301,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-301,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-301,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,"Aridis Pharmaceuticals, Inc.",Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-301,Non-traditional,Antibodies,anti-S. aureus IgM monoclonal Ab,"S. aureus HAP, VAP",IV,Phase III,"Aridis Pharmaceuticals, Inc.",Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-302,Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,"Aridis
AstraZeneca/ MedImmune",Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-302,Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,"Aridis
AstraZeneca/ MedImmune",Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-302,Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,"Aridis
AstraZeneca/ MedImmune",Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-302,Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,"Aridis
AstraZeneca/ MedImmune",Priority pathogens,Other priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-302,Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,"Aridis
AstraZeneca/ MedImmune",Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-302,Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,"Aridis
AstraZeneca/ MedImmune",Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-302,Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,"Aridis
AstraZeneca/ MedImmune",Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-302,Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,"Aridis
AstraZeneca/ MedImmune",Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-302,Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,"Aridis
AstraZeneca/ MedImmune",Priority pathogens,Enterobacterales,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-302,Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,"Aridis
AstraZeneca/ MedImmune",Priority pathogens,Critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-302,Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,"Aridis
AstraZeneca/ MedImmune",Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-302,Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,"Aridis
AstraZeneca/ MedImmune",Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,AR-302,Non-traditional,Antibodies,anti-S. aureus IgG monoclonal Ab,"S. aureus HAP, VAP",IV,Phase II,"Aridis
AstraZeneca/ MedImmune",Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,ARX-1796,Antibiotics,,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ARX-1796,Antibiotics,,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Staphylococcus aureus,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ARX-1796,Antibiotics,,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ARX-1796,Antibiotics,,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Other priority pathogens,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ARX-1796,Antibiotics,,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ARX-1796,Antibiotics,,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Helicobacter pylori,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ARX-1796,Antibiotics,,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ARX-1796,Antibiotics,,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Enterococcus faecium,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ARX-1796,Antibiotics,,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ARX-1796,Antibiotics,,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ARX-1796,Antibiotics,,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Campylobacter spp.,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ARX-1796,Antibiotics,,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ARX-1796,Antibiotics,,DBO-BLI + β-lactam,Gram-negative infections,Oral,Phase I,Pfizer/ Arixa Pharmaceuticals,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Benapenem,Antibiotics,,Carbapenem,cUTI,IV,Phase III,Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Benapenem,Antibiotics,,Carbapenem,cUTI,IV,Phase III,Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Benapenem,Antibiotics,,Carbapenem,cUTI,IV,Phase III,Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Benapenem,Antibiotics,,Carbapenem,cUTI,IV,Phase III,Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Other priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Benapenem,Antibiotics,,Carbapenem,cUTI,IV,Phase III,Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Benapenem,Antibiotics,,Carbapenem,cUTI,IV,Phase III,Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Helicobacter pylori,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Benapenem,Antibiotics,,Carbapenem,cUTI,IV,Phase III,Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Benapenem,Antibiotics,,Carbapenem,cUTI,IV,Phase III,Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Enterococcus faecium,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Benapenem,Antibiotics,,Carbapenem,cUTI,IV,Phase III,Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Benapenem,Antibiotics,,Carbapenem,cUTI,IV,Phase III,Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Benapenem,Antibiotics,,Carbapenem,cUTI,IV,Phase III,Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Campylobacter spp.,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Benapenem,Antibiotics,,Carbapenem,cUTI,IV,Phase III,Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Benapenem,Antibiotics,,Carbapenem,cUTI,IV,Phase III,Sichuan Pharmaceutical Holdings Group Ltd,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,BWC0977,Antibiotics,,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Bugworks Research,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,Yes,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,BWC0977,Antibiotics,,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Bugworks Research,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,BWC0977,Antibiotics,,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Bugworks Research,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,BWC0977,Antibiotics,,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Bugworks Research,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,BWC0977,Antibiotics,,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Bugworks Research,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,BWC0977,Antibiotics,,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Bugworks Research,Priority pathogens,Helicobacter pylori,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,BWC0977,Antibiotics,,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Bugworks Research,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,BWC0977,Antibiotics,,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Bugworks Research,Priority pathogens,Enterococcus faecium,Other priority pathogens,Yes,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,BWC0977,Antibiotics,,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Bugworks Research,Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,BWC0977,Antibiotics,,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Bugworks Research,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Possibly,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,BWC0977,Antibiotics,,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Bugworks Research,Priority pathogens,Campylobacter spp.,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,BWC0977,Antibiotics,,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Bugworks Research,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Yes,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,BWC0977,Antibiotics,,Topoisomerase,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Bugworks Research,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,BX004-A,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,BiomX,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,BX004-A,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,BiomX,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,BX004-A,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,BiomX,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,BX004-A,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,BiomX,Priority pathogens,Other priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,BX004-A,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,BiomX,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,BX004-A,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,BiomX,Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,BX004-A,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,BiomX,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,BX004-A,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,BiomX,Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,BX004-A,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,BiomX,Priority pathogens,Enterobacterales,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,BX004-A,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,BiomX,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,BX004-A,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,BiomX,Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,BX004-A,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,BiomX,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,BX004-A,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,BiomX,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CAL02,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,"Eagle Pharmaceuticals
(Combioxin SA)",Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,CAL02,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,"Eagle Pharmaceuticals
(Combioxin SA)",Priority pathogens,Staphylococcus aureus,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CAL02,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,"Eagle Pharmaceuticals
(Combioxin SA)",Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CAL02,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,"Eagle Pharmaceuticals
(Combioxin SA)",Priority pathogens,Other priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CAL02,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,"Eagle Pharmaceuticals
(Combioxin SA)",Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CAL02,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,"Eagle Pharmaceuticals
(Combioxin SA)",Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CAL02,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,"Eagle Pharmaceuticals
(Combioxin SA)",Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,CAL02,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,"Eagle Pharmaceuticals
(Combioxin SA)",Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CAL02,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,"Eagle Pharmaceuticals
(Combioxin SA)",Priority pathogens,Enterobacterales,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CAL02,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,"Eagle Pharmaceuticals
(Combioxin SA)",Priority pathogens,Critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CAL02,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,"Eagle Pharmaceuticals
(Combioxin SA)",Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CAL02,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,"Eagle Pharmaceuticals
(Combioxin SA)",Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CAL02,Non-traditional,Miscellaneous,Broad spectrum anti-toxin liposomal agent and nanoparticle,S. pneumonia severe pneumonia,IV,Phase I,"Eagle Pharmaceuticals
(Combioxin SA)",Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CF-301,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,Contrafect,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CF-301,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,Contrafect,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,CF-301,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,Contrafect,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CF-301,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,Contrafect,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,CF-301,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,Contrafect,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CF-301,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,Contrafect,Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CF-301,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,Contrafect,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,CF-301,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,Contrafect,Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CF-301,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,Contrafect,Priority pathogens,Enterobacterales,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CF-301,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,Contrafect,Priority pathogens,Critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CF-301,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,Contrafect,Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CF-301,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,Contrafect,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,CF-301,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase III,Contrafect,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Delpazolid,Antibiotics,,Oxazolidinone,"Pulmonary tuberculosis, Gram-positive bacterial infections",Oral,Phase II,"LegoChem Biosciences Inc., HaiHe Biopharma",Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,No,Yes,y,
WHO AMR pipeline analysis,Nov-21,Durlobactam + sulbactam,Antibiotics,,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,Entasis Therapeutics Inc.,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Durlobactam + sulbactam,Antibiotics,,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,Entasis Therapeutics Inc.,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Durlobactam + sulbactam,Antibiotics,,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,Entasis Therapeutics Inc.,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Durlobactam + sulbactam,Antibiotics,,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,Entasis Therapeutics Inc.,Priority pathogens,Other priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Durlobactam + sulbactam,Antibiotics,,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,Entasis Therapeutics Inc.,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Durlobactam + sulbactam,Antibiotics,,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,Entasis Therapeutics Inc.,Priority pathogens,Helicobacter pylori,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Durlobactam + sulbactam,Antibiotics,,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,Entasis Therapeutics Inc.,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Durlobactam + sulbactam,Antibiotics,,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,Entasis Therapeutics Inc.,Priority pathogens,Enterococcus faecium,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Durlobactam + sulbactam,Antibiotics,,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,Entasis Therapeutics Inc.,Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Durlobactam + sulbactam,Antibiotics,,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,Entasis Therapeutics Inc.,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Durlobactam + sulbactam,Antibiotics,,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,Entasis Therapeutics Inc.,Priority pathogens,Campylobacter spp.,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Durlobactam + sulbactam,Antibiotics,,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,Entasis Therapeutics Inc.,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Durlobactam + sulbactam,Antibiotics,,"DBO-BLI /PBP2 binder + β-lactam-BLI/PBP1,3 binder","A. baumannii HAP, VAP",IV,Phase III,Entasis Therapeutics Inc.,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,EBL-1003,Antibiotics,,Aminoglycoside,Bacterial infections,IV,Phase I,Juvabis,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,EBL-1003,Antibiotics,,Aminoglycoside,Bacterial infections,IV,Phase I,Juvabis,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,EBL-1003,Antibiotics,,Aminoglycoside,Bacterial infections,IV,Phase I,Juvabis,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,EBL-1003,Antibiotics,,Aminoglycoside,Bacterial infections,IV,Phase I,Juvabis,Priority pathogens,Other priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,EBL-1003,Antibiotics,,Aminoglycoside,Bacterial infections,IV,Phase I,Juvabis,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,EBL-1003,Antibiotics,,Aminoglycoside,Bacterial infections,IV,Phase I,Juvabis,Priority pathogens,Helicobacter pylori,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,EBL-1003,Antibiotics,,Aminoglycoside,Bacterial infections,IV,Phase I,Juvabis,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,EBL-1003,Antibiotics,,Aminoglycoside,Bacterial infections,IV,Phase I,Juvabis,Priority pathogens,Enterococcus faecium,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,EBL-1003,Antibiotics,,Aminoglycoside,Bacterial infections,IV,Phase I,Juvabis,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,EBL-1003,Antibiotics,,Aminoglycoside,Bacterial infections,IV,Phase I,Juvabis,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,EBL-1003,Antibiotics,,Aminoglycoside,Bacterial infections,IV,Phase I,Juvabis,Priority pathogens,Campylobacter spp.,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,EBL-1003,Antibiotics,,Aminoglycoside,Bacterial infections,IV,Phase I,Juvabis,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,EBL-1003,Antibiotics,,Aminoglycoside,Bacterial infections,IV,Phase I,Juvabis,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Enmetazobactam + cefepime,Antibiotics,,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,Allecra therapeutics,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Enmetazobactam + cefepime,Antibiotics,,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,Allecra therapeutics,Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Enmetazobactam + cefepime,Antibiotics,,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,Allecra therapeutics,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Enmetazobactam + cefepime,Antibiotics,,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,Allecra therapeutics,Priority pathogens,Campylobacter spp.,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Enmetazobactam + cefepime,Antibiotics,,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,Allecra therapeutics,Priority pathogens,Enterococcus faecium,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Enmetazobactam + cefepime,Antibiotics,,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,Allecra therapeutics,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Enmetazobactam + cefepime,Antibiotics,,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,Allecra therapeutics,Priority pathogens,Helicobacter pylori,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Enmetazobactam + cefepime,Antibiotics,,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,Allecra therapeutics,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Enmetazobactam + cefepime,Antibiotics,,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,Allecra therapeutics,Priority pathogens,Other priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Enmetazobactam + cefepime,Antibiotics,,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,Allecra therapeutics,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Enmetazobactam + cefepime,Antibiotics,,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,Allecra therapeutics,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Enmetazobactam + cefepime,Antibiotics,,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,Allecra therapeutics,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Enmetazobactam + cefepime,Antibiotics,,β-lactam BLI + cephalosporin,"cUTI, AP",IV,Phase III,Allecra therapeutics,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ETX0282 + cefpodoxime,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,Entasis Therapeutics Inc.,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ETX0282 + cefpodoxime,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,Entasis Therapeutics Inc.,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ETX0282 + cefpodoxime,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,Entasis Therapeutics Inc.,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ETX0282 + cefpodoxime,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,Entasis Therapeutics Inc.,Priority pathogens,Other priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ETX0282 + cefpodoxime,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,Entasis Therapeutics Inc.,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ETX0282 + cefpodoxime,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,Entasis Therapeutics Inc.,Priority pathogens,Helicobacter pylori,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ETX0282 + cefpodoxime,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,Entasis Therapeutics Inc.,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ETX0282 + cefpodoxime,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,Entasis Therapeutics Inc.,Priority pathogens,Enterococcus faecium,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ETX0282 + cefpodoxime,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,Entasis Therapeutics Inc.,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ETX0282 + cefpodoxime,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,Entasis Therapeutics Inc.,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ETX0282 + cefpodoxime,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,Entasis Therapeutics Inc.,Priority pathogens,Campylobacter spp.,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ETX0282 + cefpodoxime,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,Entasis Therapeutics Inc.,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,ETX0282 + cefpodoxime,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,"Active against ESBL, OXA-48 and KPC, but not MBL-producing Enterobacterales",Oral,Phase I,Entasis Therapeutics Inc.,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Ftortiazinon + cefepime,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Ftortiazinon + cefepime,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Ftortiazinon + cefepime,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Ftortiazinon + cefepime,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Other priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Ftortiazinon + cefepime,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Ftortiazinon + cefepime,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Ftortiazinon + cefepime,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Ftortiazinon + cefepime,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Ftortiazinon + cefepime,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Enterobacterales,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Ftortiazinon + cefepime,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Ftortiazinon + cefepime,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Ftortiazinon + cefepime,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Ftortiazinon + cefepime,Non-traditional,Miscellaneous,Type III secretion system inhibition + cefepime,P. aeruginosa cUTI,Oral,Phase II,Gamaleya Research Institute of Epidemiology and Microbiology,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Gepotidacin,Antibiotics,,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,GSK,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Gepotidacin,Antibiotics,,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,GSK,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Gepotidacin,Antibiotics,,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,GSK,Priority pathogens,Critical priority pathogens,Critical priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Gepotidacin,Antibiotics,,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,GSK,Priority pathogens,Enterobacterales,Critical priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Gepotidacin,Antibiotics,,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,GSK,Priority pathogens,Campylobacter spp.,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Gepotidacin,Antibiotics,,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,GSK,Priority pathogens,Enterococcus faecium,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Gepotidacin,Antibiotics,,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,GSK,Priority pathogens,Helicobacter pylori,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Gepotidacin,Antibiotics,,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,GSK,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Gepotidacin,Antibiotics,,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,GSK,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Gepotidacin,Antibiotics,,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,GSK,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Gepotidacin,Antibiotics,,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,GSK,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Gepotidacin,Antibiotics,,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,GSK,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Gepotidacin,Antibiotics,,Topoisomerase Inhibitors (Triazaacenaphthylene),Uncomplicated urogenital gonorrhea and uUTI,"IV, Oral",Phase III,GSK,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,GSK3882347,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,GSK,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,GSK3882347,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,GSK,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,GSK3882347,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,GSK,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,GSK3882347,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,GSK,Priority pathogens,Other priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,GSK3882347,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,GSK,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,GSK3882347,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,GSK,Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,GSK3882347,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,GSK,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,GSK3882347,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,GSK,Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,GSK3882347,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,GSK,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,GSK3882347,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,GSK,Priority pathogens,Critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,GSK3882347,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,GSK,Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,GSK3882347,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,GSK,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,GSK3882347,Non-traditional,Miscellaneous,Undisclosed (FimH),E.coli UTI,Oral,Phase I,GSK,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,KBP-7072,Antibiotics,,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,KBP-7072,Antibiotics,,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,KBP-7072,Antibiotics,,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,KBP-7072,Antibiotics,,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,KBP-7072,Antibiotics,,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,KBP-7072,Antibiotics,,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Helicobacter pylori,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,KBP-7072,Antibiotics,,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,KBP-7072,Antibiotics,,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Enterococcus faecium,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,KBP-7072,Antibiotics,,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,KBP-7072,Antibiotics,,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,KBP-7072,Antibiotics,,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Campylobacter spp.,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,KBP-7072,Antibiotics,,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,KBP-7072,Antibiotics,,Tetracycline,"Multi-drug resistant bacterial infections including (CABP, DFI, cUTI, cIAI)",Oral,Phase I,"KBP BioSciences Pharmaceutical Technical Co., Ltd.",Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,LBP-EC01,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,Locus Bioscience,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LBP-EC01,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,Locus Bioscience,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LBP-EC01,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,Locus Bioscience,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LBP-EC01,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,Locus Bioscience,Priority pathogens,Other priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LBP-EC01,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,Locus Bioscience,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LBP-EC01,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,Locus Bioscience,Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LBP-EC01,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,Locus Bioscience,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LBP-EC01,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,Locus Bioscience,Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LBP-EC01,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,Locus Bioscience,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,LBP-EC01,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,Locus Bioscience,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,LBP-EC01,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,Locus Bioscience,Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LBP-EC01,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,Locus Bioscience,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LBP-EC01,Non-traditional,Bacteriophages and phage-derived enzymes,CRISPR-Cas3 enhanced phage,E. coli,IV,Phase I,Locus Bioscience,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LMN-101,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,Lumen Bioscience,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LMN-101,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,Lumen Bioscience,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LMN-101,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,Lumen Bioscience,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LMN-101,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,Lumen Bioscience,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,LMN-101,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,Lumen Bioscience,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LMN-101,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,Lumen Bioscience,Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LMN-101,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,Lumen Bioscience,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LMN-101,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,Lumen Bioscience,Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LMN-101,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,Lumen Bioscience,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,LMN-101,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,Lumen Bioscience,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,LMN-101,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,Lumen Bioscience,Priority pathogens,Campylobacter spp.,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,LMN-101,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,Lumen Bioscience,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LMN-101,Non-traditional,Antibodies,"Monoclonal Ab like
recombinant protein",E. coli and  C. jejuni infections,Oral,Phase II,Lumen Bioscience,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LSVT-1701,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LSVT-1701,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,LSVT-1701,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LSVT-1701,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Other priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LSVT-1701,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LSVT-1701,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LSVT-1701,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,LSVT-1701,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LSVT-1701,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Enterobacterales,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LSVT-1701,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LSVT-1701,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LSVT-1701,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,Roivant Sciences/iNtRON Biotechnology,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,LSVT-1701,Non-traditional,Bacteriophages and phage-derived enzymes,Phage endolysin,S. aureus bacteremia,IV,Phase II,Roivant Sciences/iNtRON Biotechnology,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,MRX-8,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,MicuRx,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,MRX-8,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,MicuRx,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,MRX-8,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,MicuRx,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,MRX-8,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,MicuRx,Priority pathogens,Other priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,MRX-8,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,MicuRx,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,MRX-8,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,MicuRx,Priority pathogens,Helicobacter pylori,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,MRX-8,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,MicuRx,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,MRX-8,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,MicuRx,Priority pathogens,Enterococcus faecium,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,MRX-8,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,MicuRx,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,MRX-8,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,MicuRx,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,MRX-8,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,MicuRx,Priority pathogens,Campylobacter spp.,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,MRX-8,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,MicuRx,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,MRX-8,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,MicuRx,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nacubactam + meropenem,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,Meiji Seika,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nacubactam + meropenem,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,Meiji Seika,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nacubactam + meropenem,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,Meiji Seika,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nacubactam + meropenem,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,Meiji Seika,Priority pathogens,Other priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nacubactam + meropenem,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,Meiji Seika,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nacubactam + meropenem,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,Meiji Seika,Priority pathogens,Helicobacter pylori,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nacubactam + meropenem,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,Meiji Seika,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nacubactam + meropenem,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,Meiji Seika,Priority pathogens,Enterococcus faecium,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nacubactam + meropenem,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,Meiji Seika,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nacubactam + meropenem,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,Meiji Seika,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nacubactam + meropenem,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,Meiji Seika,Priority pathogens,Campylobacter spp.,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nacubactam + meropenem,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,Meiji Seika,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nacubactam + meropenem,Antibiotics,,DBO-BLI/PBP2 binder + cephalosporin,Bacterial infections,IV,Phase I,Meiji Seika,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nafithromycin,Antibiotics,,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,Wockhardt Ltd.,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nafithromycin,Antibiotics,,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,Wockhardt Ltd.,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nafithromycin,Antibiotics,,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,Wockhardt Ltd.,Priority pathogens,Critical priority pathogens,Critical priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nafithromycin,Antibiotics,,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,Wockhardt Ltd.,Priority pathogens,Enterobacterales,Critical priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nafithromycin,Antibiotics,,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,Wockhardt Ltd.,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nafithromycin,Antibiotics,,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,Wockhardt Ltd.,Priority pathogens,Campylobacter spp.,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nafithromycin,Antibiotics,,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,Wockhardt Ltd.,Priority pathogens,Enterococcus faecium,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nafithromycin,Antibiotics,,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,Wockhardt Ltd.,Priority pathogens,Helicobacter pylori,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nafithromycin,Antibiotics,,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,Wockhardt Ltd.,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nafithromycin,Antibiotics,,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,Wockhardt Ltd.,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nafithromycin,Antibiotics,,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,Wockhardt Ltd.,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nafithromycin,Antibiotics,,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,Wockhardt Ltd.,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Nafithromycin,Antibiotics,,Macrolide,CABP (caused by S. pneumoniae and S. aureus),Oral,Phase III,Wockhardt Ltd.,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,OligoG,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,AlgiPharma AS,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,OligoG,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,AlgiPharma AS,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,OligoG,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,AlgiPharma AS,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,OligoG,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,AlgiPharma AS,Priority pathogens,Other priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,OligoG,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,AlgiPharma AS,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,OligoG,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,AlgiPharma AS,Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,OligoG,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,AlgiPharma AS,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,OligoG,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,AlgiPharma AS,Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,OligoG,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,AlgiPharma AS,Priority pathogens,Enterobacterales,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,OligoG,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,AlgiPharma AS,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,OligoG,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,AlgiPharma AS,Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,OligoG,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,AlgiPharma AS,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,OligoG,Non-traditional,Miscellaneous,Alginate oligosaccharide (G-block) fragment,Cystic fibrosis,Inhalation,Phase II,AlgiPharma AS,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Phage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,"Adaptive Phage
Therapeutics",Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Phage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,"Adaptive Phage
Therapeutics",Priority pathogens,Staphylococcus aureus,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Phage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,"Adaptive Phage
Therapeutics",Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Phage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,"Adaptive Phage
Therapeutics",Priority pathogens,Other priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Phage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,"Adaptive Phage
Therapeutics",Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Phage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,"Adaptive Phage
Therapeutics",Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Phage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,"Adaptive Phage
Therapeutics",Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Phage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,"Adaptive Phage
Therapeutics",Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Phage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,"Adaptive Phage
Therapeutics",Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Phage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,"Adaptive Phage
Therapeutics",Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Phage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,"Adaptive Phage
Therapeutics",Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Phage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,"Adaptive Phage
Therapeutics",Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Phage,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,E. coli,IV,Phase II,"Adaptive Phage
Therapeutics",Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2014,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2014,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2014,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2014,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Other priority pathogens,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2014,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2014,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Helicobacter pylori,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2014,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2014,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Enterococcus faecium,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2014,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2014,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2014,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Campylobacter spp.,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2014,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Yes,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2014,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2015,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,Qpex Biopharma,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2015,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,Qpex Biopharma,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2015,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,Qpex Biopharma,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2015,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,Qpex Biopharma,Priority pathogens,Other priority pathogens,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2015,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,Qpex Biopharma,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2015,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,Qpex Biopharma,Priority pathogens,Helicobacter pylori,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2015,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,Qpex Biopharma,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2015,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,Qpex Biopharma,Priority pathogens,Enterococcus faecium,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2015,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,Qpex Biopharma,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2015,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,Qpex Biopharma,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2015,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,Qpex Biopharma,Priority pathogens,Campylobacter spp.,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2015,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,Qpex Biopharma,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Possibly,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX7728 + QPX2015,Antibiotics,,Boronate-BLI + undisclosed,Gram-negative infections,Oral,Phase I,Qpex Biopharma,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX9003,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX9003,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX9003,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX9003,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Other priority pathogens,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX9003,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX9003,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Helicobacter pylori,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX9003,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX9003,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Enterococcus faecium,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX9003,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX9003,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Possibly,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX9003,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Campylobacter spp.,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX9003,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Possibly,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,QPX9003,Antibiotics,,Polymyxin,Gram-negative infections,IV,Phase I,Qpex Biopharma,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,RG6006,Antibiotics,,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Roche,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,RG6006,Antibiotics,,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Roche,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,RG6006,Antibiotics,,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Roche,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,RG6006,Antibiotics,,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Roche,Priority pathogens,Other priority pathogens,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,RG6006,Antibiotics,,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Roche,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,RG6006,Antibiotics,,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Roche,Priority pathogens,Helicobacter pylori,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,RG6006,Antibiotics,,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Roche,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,RG6006,Antibiotics,,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Roche,Priority pathogens,Enterococcus faecium,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,RG6006,Antibiotics,,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Roche,Priority pathogens,Enterobacterales,Critical priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,RG6006,Antibiotics,,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Roche,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Possibly,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,RG6006,Antibiotics,,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Roche,Priority pathogens,Campylobacter spp.,Other priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,RG6006,Antibiotics,,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Roche,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,RG6006,Antibiotics,,Macrocyclic peptide,Acinetobacter infections,IV,Phase I,Roche,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,Inconclusive,Yes,,
WHO AMR pipeline analysis,Nov-21,Rhu-pGSN,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,BioAegis Therapeutics,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Rhu-pGSN,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,BioAegis Therapeutics,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Rhu-pGSN,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,BioAegis Therapeutics,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Rhu-pGSN,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,BioAegis Therapeutics,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Rhu-pGSN,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,BioAegis Therapeutics,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Rhu-pGSN,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,BioAegis Therapeutics,Priority pathogens,Helicobacter pylori,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Rhu-pGSN,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,BioAegis Therapeutics,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Rhu-pGSN,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,BioAegis Therapeutics,Priority pathogens,Enterococcus faecium,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Rhu-pGSN,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,BioAegis Therapeutics,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Rhu-pGSN,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,BioAegis Therapeutics,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Rhu-pGSN,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,BioAegis Therapeutics,Priority pathogens,Campylobacter spp.,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Rhu-pGSN,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,BioAegis Therapeutics,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Rhu-pGSN,Non-traditional,Immunomodulating agents,Recombinant human plasma gelsolin protein,Hospitalized CAP,IV,Phase II,BioAegis Therapeutics,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,Solithromycin,Antibiotics,,Macrolide,S. pneumoniae,IV & oral,Preregistration,"Fujfilm Toyama
Chemical",Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Solithromycin,Antibiotics,,Macrolide,S. pneumoniae,IV & oral,Preregistration,"Fujfilm Toyama
Chemical",Priority pathogens,Staphylococcus aureus,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Solithromycin,Antibiotics,,Macrolide,S. pneumoniae,IV & oral,Preregistration,"Fujfilm Toyama
Chemical",Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Solithromycin,Antibiotics,,Macrolide,S. pneumoniae,IV & oral,Preregistration,"Fujfilm Toyama
Chemical",Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Solithromycin,Antibiotics,,Macrolide,S. pneumoniae,IV & oral,Preregistration,"Fujfilm Toyama
Chemical",Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Solithromycin,Antibiotics,,Macrolide,S. pneumoniae,IV & oral,Preregistration,"Fujfilm Toyama
Chemical",Priority pathogens,Helicobacter pylori,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Solithromycin,Antibiotics,,Macrolide,S. pneumoniae,IV & oral,Preregistration,"Fujfilm Toyama
Chemical",Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Solithromycin,Antibiotics,,Macrolide,S. pneumoniae,IV & oral,Preregistration,"Fujfilm Toyama
Chemical",Priority pathogens,Enterococcus faecium,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Solithromycin,Antibiotics,,Macrolide,S. pneumoniae,IV & oral,Preregistration,"Fujfilm Toyama
Chemical",Priority pathogens,Enterobacterales,Critical priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Solithromycin,Antibiotics,,Macrolide,S. pneumoniae,IV & oral,Preregistration,"Fujfilm Toyama
Chemical",Priority pathogens,Critical priority pathogens,Critical priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Solithromycin,Antibiotics,,Macrolide,S. pneumoniae,IV & oral,Preregistration,"Fujfilm Toyama
Chemical",Priority pathogens,Campylobacter spp.,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Solithromycin,Antibiotics,,Macrolide,S. pneumoniae,IV & oral,Preregistration,"Fujfilm Toyama
Chemical",Priority pathogens,All critical priority pathogens,Critical priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Solithromycin,Antibiotics,,Macrolide,S. pneumoniae,IV & oral,Preregistration,"Fujfilm Toyama
Chemical",Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,SPR-206,Antibiotics,,Polymyxin,Acinetobacter infections,IV,Phase I,Spero Therapeutics,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,SPR-206,Antibiotics,,Polymyxin,Acinetobacter infections,IV,Phase I,Spero Therapeutics,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,SPR-206,Antibiotics,,Polymyxin,Acinetobacter infections,IV,Phase I,Spero Therapeutics,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,SPR-206,Antibiotics,,Polymyxin,Acinetobacter infections,IV,Phase I,Spero Therapeutics,Priority pathogens,Other priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,SPR-206,Antibiotics,,Polymyxin,Acinetobacter infections,IV,Phase I,Spero Therapeutics,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,SPR-206,Antibiotics,,Polymyxin,Acinetobacter infections,IV,Phase I,Spero Therapeutics,Priority pathogens,Helicobacter pylori,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,SPR-206,Antibiotics,,Polymyxin,Acinetobacter infections,IV,Phase I,Spero Therapeutics,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,SPR-206,Antibiotics,,Polymyxin,Acinetobacter infections,IV,Phase I,Spero Therapeutics,Priority pathogens,Enterococcus faecium,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,SPR-206,Antibiotics,,Polymyxin,Acinetobacter infections,IV,Phase I,Spero Therapeutics,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,SPR-206,Antibiotics,,Polymyxin,Acinetobacter infections,IV,Phase I,Spero Therapeutics,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,SPR-206,Antibiotics,,Polymyxin,Acinetobacter infections,IV,Phase I,Spero Therapeutics,Priority pathogens,Campylobacter spp.,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,SPR-206,Antibiotics,,Polymyxin,Acinetobacter infections,IV,Phase I,Spero Therapeutics,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,SPR-206,Antibiotics,,Polymyxin,Acinetobacter infections,IV,Phase I,Spero Therapeutics,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"Sulopenem, sulopenem etzadroxil/probenecid",Antibiotics,,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,Iterum Therapeutics,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"Sulopenem, sulopenem etzadroxil/probenecid",Antibiotics,,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,Iterum Therapeutics,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"Sulopenem, sulopenem etzadroxil/probenecid",Antibiotics,,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,Iterum Therapeutics,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"Sulopenem, sulopenem etzadroxil/probenecid",Antibiotics,,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,Iterum Therapeutics,Priority pathogens,Other priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"Sulopenem, sulopenem etzadroxil/probenecid",Antibiotics,,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,Iterum Therapeutics,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"Sulopenem, sulopenem etzadroxil/probenecid",Antibiotics,,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,Iterum Therapeutics,Priority pathogens,Helicobacter pylori,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"Sulopenem, sulopenem etzadroxil/probenecid",Antibiotics,,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,Iterum Therapeutics,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"Sulopenem, sulopenem etzadroxil/probenecid",Antibiotics,,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,Iterum Therapeutics,Priority pathogens,Enterococcus faecium,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"Sulopenem, sulopenem etzadroxil/probenecid",Antibiotics,,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,Iterum Therapeutics,Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"Sulopenem, sulopenem etzadroxil/probenecid",Antibiotics,,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,Iterum Therapeutics,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"Sulopenem, sulopenem etzadroxil/probenecid",Antibiotics,,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,Iterum Therapeutics,Priority pathogens,Campylobacter spp.,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"Sulopenem, sulopenem etzadroxil/probenecid",Antibiotics,,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,Iterum Therapeutics,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"Sulopenem, sulopenem etzadroxil/probenecid",Antibiotics,,β-Lactam (penem),"uUTI, cUTI, IAI","IV, Oral",Phase III,Iterum Therapeutics,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,SVT-1C469,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,Servatus,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,SVT-1C469,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,Servatus,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,SVT-1C469,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,Servatus,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,SVT-1C469,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,Servatus,Priority pathogens,Other priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,SVT-1C469,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,Servatus,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,SVT-1C469,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,Servatus,Priority pathogens,Helicobacter pylori,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,SVT-1C469,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,Servatus,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,SVT-1C469,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,Servatus,Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,SVT-1C469,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,Servatus,Priority pathogens,Enterobacterales,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,SVT-1C469,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,Servatus,Priority pathogens,Critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,SVT-1C469,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,Servatus,Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,SVT-1C469,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,Servatus,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,SVT-1C469,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,H. pylori,Oral,Phase I,Servatus,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Taniborbactam + cefepime,Antibiotics,,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Taniborbactam + cefepime,Antibiotics,,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Staphylococcus aureus,Other priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Taniborbactam + cefepime,Antibiotics,,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Taniborbactam + cefepime,Antibiotics,,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Other priority pathogens,Other priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Taniborbactam + cefepime,Antibiotics,,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Taniborbactam + cefepime,Antibiotics,,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Helicobacter pylori,Other priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Taniborbactam + cefepime,Antibiotics,,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Taniborbactam + cefepime,Antibiotics,,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Enterococcus faecium,Other priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Taniborbactam + cefepime,Antibiotics,,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Taniborbactam + cefepime,Antibiotics,,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Taniborbactam + cefepime,Antibiotics,,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Campylobacter spp.,Other priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Taniborbactam + cefepime,Antibiotics,,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Taniborbactam + cefepime,Antibiotics,,Boronate BLI + β-lactam (cephalosporin),cUTI and AP,IV,Phase III,"VenatoRx Pharmaceuticals, Inc/ GARDP",Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2092,Antibiotics,,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,Tennor Therapeutics,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2092,Antibiotics,,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,Tennor Therapeutics,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2092,Antibiotics,,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,Tennor Therapeutics,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2092,Antibiotics,,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,Tennor Therapeutics,Priority pathogens,Other priority pathogens,Other priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2092,Antibiotics,,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,Tennor Therapeutics,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2092,Antibiotics,,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,Tennor Therapeutics,Priority pathogens,Helicobacter pylori,Other priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2092,Antibiotics,,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,Tennor Therapeutics,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2092,Antibiotics,,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,Tennor Therapeutics,Priority pathogens,Enterococcus faecium,Other priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2092,Antibiotics,,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,Tennor Therapeutics,Priority pathogens,Enterobacterales,Critical priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2092,Antibiotics,,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,Tennor Therapeutics,Priority pathogens,Critical priority pathogens,Critical priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2092,Antibiotics,,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,Tennor Therapeutics,Priority pathogens,Campylobacter spp.,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2092,Antibiotics,,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,Tennor Therapeutics,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2092,Antibiotics,,Rifamycin-quinolizinone hybrid,Gastrointestinal infections (caused by S. aureus and H. pylori),"IV, Oral",Phase II,Tennor Therapeutics,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2198,Antibiotics,,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,TenNor Therapeutics,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2198,Antibiotics,,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,TenNor Therapeutics,Priority pathogens,Staphylococcus aureus,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2198,Antibiotics,,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,TenNor Therapeutics,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2198,Antibiotics,,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,TenNor Therapeutics,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2198,Antibiotics,,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,TenNor Therapeutics,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2198,Antibiotics,,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,TenNor Therapeutics,Priority pathogens,Helicobacter pylori,Other priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2198,Antibiotics,,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,TenNor Therapeutics,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,No,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2198,Antibiotics,,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,TenNor Therapeutics,Priority pathogens,Enterococcus faecium,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2198,Antibiotics,,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,TenNor Therapeutics,Priority pathogens,Enterobacterales,Critical priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2198,Antibiotics,,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,TenNor Therapeutics,Priority pathogens,Critical priority pathogens,Critical priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2198,Antibiotics,,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,TenNor Therapeutics,Priority pathogens,Campylobacter spp.,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2198,Antibiotics,,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,TenNor Therapeutics,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TNP-2198,Antibiotics,,rifamycin-nitroimidazole conjugate,"Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis",Oral,Phase II,TenNor Therapeutics,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,TRL1068,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Trellis Bioscience,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,TRL1068,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Trellis Bioscience,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,TRL1068,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Trellis Bioscience,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,TRL1068,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Trellis Bioscience,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,TRL1068,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Trellis Bioscience,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,TRL1068,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Trellis Bioscience,Priority pathogens,Helicobacter pylori,Other priority pathogens,Possibly,,Yes,,
WHO AMR pipeline analysis,Nov-21,TRL1068,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Trellis Bioscience,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,TRL1068,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Trellis Bioscience,Priority pathogens,Enterococcus faecium,Other priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,TRL1068,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Trellis Bioscience,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,TRL1068,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Trellis Bioscience,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,TRL1068,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Trellis Bioscience,Priority pathogens,Campylobacter spp.,Other priority pathogens,Possibly,,Yes,,
WHO AMR pipeline analysis,Nov-21,TRL1068,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Trellis Bioscience,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,TRL1068,Non-traditional,Antibodies,Antibody,Gram-negative and Gram-positive bacterial infections,IV,Phase I,Trellis Bioscience,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,TXA709,Antibiotics,,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,TAXIS Pharmaceuticals,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,TXA709,Antibiotics,,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,TAXIS Pharmaceuticals,Priority pathogens,Staphylococcus aureus,Other priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,TXA709,Antibiotics,,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,TAXIS Pharmaceuticals,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,TXA709,Antibiotics,,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,TAXIS Pharmaceuticals,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,TXA709,Antibiotics,,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,TAXIS Pharmaceuticals,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,TXA709,Antibiotics,,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,TAXIS Pharmaceuticals,Priority pathogens,Helicobacter pylori,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,TXA709,Antibiotics,,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,TAXIS Pharmaceuticals,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,TXA709,Antibiotics,,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,TAXIS Pharmaceuticals,Priority pathogens,Enterococcus faecium,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,TXA709,Antibiotics,,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,TAXIS Pharmaceuticals,Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,TXA709,Antibiotics,,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,TAXIS Pharmaceuticals,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,TXA709,Antibiotics,,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,TAXIS Pharmaceuticals,Priority pathogens,Campylobacter spp.,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,TXA709,Antibiotics,,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,TAXIS Pharmaceuticals,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,TXA709,Antibiotics,,Diflurobenzamide (FtsZ inhibitor),MRSA,"IV, Oral",Phase I,TAXIS Pharmaceuticals,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,VNRX-7145 + ceftibuten,Antibiotics,,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,Venatorx,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,VNRX-7145 + ceftibuten,Antibiotics,,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,Venatorx,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,VNRX-7145 + ceftibuten,Antibiotics,,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,Venatorx,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,VNRX-7145 + ceftibuten,Antibiotics,,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,Venatorx,Priority pathogens,Other priority pathogens,Other priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,VNRX-7145 + ceftibuten,Antibiotics,,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,Venatorx,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,VNRX-7145 + ceftibuten,Antibiotics,,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,Venatorx,Priority pathogens,Helicobacter pylori,Other priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,VNRX-7145 + ceftibuten,Antibiotics,,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,Venatorx,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,VNRX-7145 + ceftibuten,Antibiotics,,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,Venatorx,Priority pathogens,Enterococcus faecium,Other priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,VNRX-7145 + ceftibuten,Antibiotics,,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,Venatorx,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,VNRX-7145 + ceftibuten,Antibiotics,,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,Venatorx,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,VNRX-7145 + ceftibuten,Antibiotics,,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,Venatorx,Priority pathogens,Campylobacter spp.,Other priority pathogens,,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,VNRX-7145 + ceftibuten,Antibiotics,,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,Venatorx,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,VNRX-7145 + ceftibuten,Antibiotics,,Boronate-BLI + cephalosporin,Gram-negative infections,Oral,Phase I,Venatorx,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,"XNW4107 +imipenem 
+ cilastin",Antibiotics,,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,Sinovent,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"XNW4107 +imipenem 
+ cilastin",Antibiotics,,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,Sinovent,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"XNW4107 +imipenem 
+ cilastin",Antibiotics,,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,Sinovent,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"XNW4107 +imipenem 
+ cilastin",Antibiotics,,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,Sinovent,Priority pathogens,Other priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"XNW4107 +imipenem 
+ cilastin",Antibiotics,,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,Sinovent,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"XNW4107 +imipenem 
+ cilastin",Antibiotics,,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,Sinovent,Priority pathogens,Helicobacter pylori,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"XNW4107 +imipenem 
+ cilastin",Antibiotics,,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,Sinovent,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"XNW4107 +imipenem 
+ cilastin",Antibiotics,,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,Sinovent,Priority pathogens,Enterococcus faecium,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"XNW4107 +imipenem 
+ cilastin",Antibiotics,,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,Sinovent,Priority pathogens,Enterobacterales,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"XNW4107 +imipenem 
+ cilastin",Antibiotics,,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,Sinovent,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"XNW4107 +imipenem 
+ cilastin",Antibiotics,,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,Sinovent,Priority pathogens,Campylobacter spp.,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"XNW4107 +imipenem 
+ cilastin",Antibiotics,,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,Sinovent,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,"XNW4107 +imipenem 
+ cilastin",Antibiotics,,"BLI + carbapenem + 
degradation inhibitor",HABP/VABP,IV,Phase I,Sinovent,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Possibly,No,Yes,,
WHO AMR pipeline analysis,Nov-21,YPT-01,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Felix Biotechnology/ Yale University,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,YPT-01,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Felix Biotechnology/ Yale University,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,YPT-01,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Felix Biotechnology/ Yale University,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,YPT-01,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Felix Biotechnology/ Yale University,Priority pathogens,Other priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,YPT-01,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Felix Biotechnology/ Yale University,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,YPT-01,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Felix Biotechnology/ Yale University,Priority pathogens,Helicobacter pylori,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,YPT-01,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Felix Biotechnology/ Yale University,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,YPT-01,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Felix Biotechnology/ Yale University,Priority pathogens,Enterococcus faecium,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,YPT-01,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Felix Biotechnology/ Yale University,Priority pathogens,Enterobacterales,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,YPT-01,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Felix Biotechnology/ Yale University,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,,Yes,,
WHO AMR pipeline analysis,Nov-21,YPT-01,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Felix Biotechnology/ Yale University,Priority pathogens,Campylobacter spp.,Other priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,YPT-01,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Felix Biotechnology/ Yale University,Priority pathogens,All critical priority pathogens,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,YPT-01,Non-traditional,Bacteriophages and phage-derived enzymes,Bacteriophage,CF subjects with P. aeruginosa infections,Inhalation,Phase II,Felix Biotechnology/ Yale University,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,,,Yes,,
WHO AMR pipeline analysis,Nov-21,Zidebactam + cefepime,Antibiotics,,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,Wockhardt Ltd.,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Zidebactam + cefepime,Antibiotics,,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,Wockhardt Ltd.,Priority pathogens,Staphylococcus aureus,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Zidebactam + cefepime,Antibiotics,,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,Wockhardt Ltd.,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Zidebactam + cefepime,Antibiotics,,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,Wockhardt Ltd.,Priority pathogens,Other priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Zidebactam + cefepime,Antibiotics,,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,Wockhardt Ltd.,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Zidebactam + cefepime,Antibiotics,,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,Wockhardt Ltd.,Priority pathogens,Helicobacter pylori,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Zidebactam + cefepime,Antibiotics,,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,Wockhardt Ltd.,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Zidebactam + cefepime,Antibiotics,,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,Wockhardt Ltd.,Priority pathogens,Enterococcus faecium,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Zidebactam + cefepime,Antibiotics,,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,Wockhardt Ltd.,Priority pathogens,Enterobacterales,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Zidebactam + cefepime,Antibiotics,,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,Wockhardt Ltd.,Priority pathogens,Critical priority pathogens,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Zidebactam + cefepime,Antibiotics,,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,Wockhardt Ltd.,Priority pathogens,Campylobacter spp.,Other priority pathogens,,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Zidebactam + cefepime,Antibiotics,,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,Wockhardt Ltd.,Priority pathogens,All critical priority pathogens,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Zidebactam + cefepime,Antibiotics,,DBO-BLI/ PBP2 binder + cephalosporin,Gram-negative bacterial infections,IV,Phase I,Wockhardt Ltd.,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,Yes,No,Yes,,
WHO AMR pipeline analysis,Nov-21,Zoliflodacin,Antibiotics,,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Streptococcus pneumoniae,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Zoliflodacin,Antibiotics,,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Staphylococcus aureus,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Zoliflodacin,Antibiotics,,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Pseudomonas aeruginosa,Critical priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Zoliflodacin,Antibiotics,,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Other priority pathogens,Other priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Zoliflodacin,Antibiotics,,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Neisseria gonnorhoeae,Other priority pathogens,Yes,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Zoliflodacin,Antibiotics,,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Helicobacter pylori,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Zoliflodacin,Antibiotics,,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Gram-positive priority pathogens,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Zoliflodacin,Antibiotics,,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Enterococcus faecium,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Zoliflodacin,Antibiotics,,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Enterobacterales,Critical priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Zoliflodacin,Antibiotics,,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Critical priority pathogens,Critical priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Zoliflodacin,Antibiotics,,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Campylobacter spp.,Other priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Zoliflodacin,Antibiotics,,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,Entasis Therapeutics Inc./ GARDP,Priority pathogens,All critical priority pathogens,Critical priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,Zoliflodacin,Antibiotics,,Topoisomerase Inhibitors (Spiropyrimidenetrione),Uncomplicated N. gonorrhoeae,Oral,Phase III,Entasis Therapeutics Inc./ GARDP,Priority pathogens,Acinetobacter baumannii,Critical priority pathogens,No,Yes,Yes,,
WHO AMR pipeline analysis,Nov-21,GSK3036656,Antibiotics,,Leu RS inhibitor (oxaborole),Pulmonary tuberculosis,Oral,Phase II,GlaxoSmithKline PLC,Mycobacterium tuberculosis,Mycobacterium tuberculosis,,,Yes,Yes,y,
WHO AMR pipeline analysis,Nov-21,BTZ-043,Antibiotics,,DprE1 inhibitor (benzothiazinone),Tuberculosis,Oral,Phase II,"University of Munich; Hans Knöll Institute, Jena; German Center for Infection Research",Mycobacterium tuberculosis,Mycobacterium tuberculosis,,,Yes,Yes,y,
WHO AMR pipeline analysis,Nov-21,BVL-GSK098,Non-traditional,Miscellaneous,"Amido piperidine (inactivation of TetR-like repressor, EthR2)",Tuberculosis,Oral,Phase I,Bioversys/ GSK,Mycobacterium tuberculosis,Mycobacterium tuberculosis,,,,Yes,y,
WHO AMR pipeline analysis,Nov-21,Delpazolid,Antibiotics,,Oxazolidinone,"Pulmonary tuberculosis, Gram-positive bacterial infections",Oral,Phase II,"LegoChem Biosciences Inc., HaiHe Biopharma",Mycobacterium tuberculosis,Mycobacterium tuberculosis,,,No,Yes,y,
WHO AMR pipeline analysis,Nov-21,GSK2556286,Antibiotics,,Undisclosed,Tuberculosis,Oral,Phase I,GSK. TB Drug Accelarator/ Bill & Melinda Gates Foundation,Mycobacterium tuberculosis,Mycobacterium tuberculosis,,,Yes,Yes,y,
WHO AMR pipeline analysis,Nov-21,Macozinone,Antibiotics,,DprE1 inhibitor (Benzothiazinone),Pulmonary tuberculosis,Oral,Phase I,Innovative Medicines for Tuberculosis Foundation and Nearmedic Plus,Mycobacterium tuberculosis,Mycobacterium tuberculosis,,,Yes,Yes,y,
WHO AMR pipeline analysis,Nov-21,OPC-167832,Antibiotics,,"DprE1 inhibitor (3,4-dihydrocarbostyril)",Pulmonary tuberculosis,Oral,Phase II,"Otsuka Pharmaceutical Co., Ltd.",Mycobacterium tuberculosis,Mycobacterium tuberculosis,,,Yes,Yes,y,
WHO AMR pipeline analysis,Nov-21,Sutezolid,Antibiotics,,Oxazolidinone,"Pulmonary tuberculosis, Gram-positive bacterial infections",Oral,Phase II,TB Alliance/ Sequella,Mycobacterium tuberculosis,Mycobacterium tuberculosis,,,No,Yes,y,
WHO AMR pipeline analysis,Nov-21,TBA-7371,Antibiotics,,DprE1 inhibitor (azaindole),Tuberculosis,Oral,Phase II,TB Alliance/ Bill & Melinda Gates Medical Research Institute/ Foundation for Neglected Disease Research,Mycobacterium tuberculosis,Mycobacterium tuberculosis,,,Yes,Yes,y,
WHO AMR pipeline analysis,Nov-21,TBAJ-587,Antibiotics,,Diarylquinoline,Tuberculosis,Oral,Phase I,TB Alliance,Mycobacterium tuberculosis,Mycobacterium tuberculosis,,,No,Yes,y,
WHO AMR pipeline analysis,Nov-21,TBAJ-876,Antibiotics,,Diarylquinoline,Tuberculosis,Oral,Phase I,TB Alliance,Mycobacterium tuberculosis,Mycobacterium tuberculosis,,,No,Yes,y,
WHO AMR pipeline analysis,Nov-21,TBI-166,Antibiotics,,Riminophenazine (clofazimine-analogue),Tuberculosis,Oral,Phase I,"Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College",Mycobacterium tuberculosis,Mycobacterium tuberculosis,,,No,Yes,y,
WHO AMR pipeline analysis,Nov-21,TBI-223,Antibiotics,,Oxazolidinone,Tuberculosis,Oral,Phase I,Institute of Materia Medica/ TB Alliance,Mycobacterium tuberculosis,Mycobacterium tuberculosis,,,No,Yes,y,
WHO AMR pipeline analysis,Nov-21,Telacebec,Antibiotics,,Imidazopyridine amide,Pulmonary tuberculosis,Oral,Phase II,Qurient Co,Mycobacterium tuberculosis,Mycobacterium tuberculosis,,,Yes,Yes,y,
WHO AMR pipeline analysis,Nov-21,ART24,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,C. difficile infections,Oral,Phase I,Artugen Therapeutics,Clostridioides difficile,Clostridioides difficile,,,,Yes,,y
WHO AMR pipeline analysis,Nov-21,BB128,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,Recurring C. difficile infections,Colonoscopy,Preregistration,BiomeBank,Clostridioides difficile,Clostridioides difficile,,,,Yes,,y
WHO AMR pipeline analysis,Nov-21,CP101,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,Recurring C. difficile infections,Oral,Phase II,Finch Theraputics,Clostridioides difficile,Clostridioides difficile,,,,Yes,,y
WHO AMR pipeline analysis,Nov-21,CRS3123,Antibiotics,,Diaryldiamine (Methionyl-tRNA synthetase inhibitor),C. difficile infections,Oral,Phase II,Crestone/ National Institute of Allergy and Infectious Diseases,Clostridioides difficile,Clostridioides difficile,,,Yes,Yes,,y
WHO AMR pipeline analysis,Nov-21,DAV132,Non-traditional,Microbiome-modulating agents,Antibiotic inactivator and protective colon-targeted adsorbent,C. difficile infections,Oral,Phase II,Da Volterra,Clostridioides difficile,Clostridioides difficile,,,,Yes,,y
WHO AMR pipeline analysis,Nov-21,DNV3837,Antibiotics,,Oxazolidinone-quinolone hybrid,C. difficile infections,IV,Phase II,Deinove,Clostridioides difficile,Clostridioides difficile,,,Inconclusive,Yes,,y
WHO AMR pipeline analysis,Nov-21,Ibezapolstat,Antibiotics,,Substituted guanine (DNA polymerae IIIIC inhibitor)),C. difficile infections,"Oral, Not absorbed",Phase II,Acurx Pharmaceuticals,Clostridioides difficile,Clostridioides difficile,,,Yes,Yes,,y
WHO AMR pipeline analysis,Nov-21,IM-01,Non-traditional,Antibodies,anti-C. difficile polcyclonal Ab,C. difficile infections,Oral,Phase II,ImmuniMed,Clostridioides difficile,Clostridioides difficile,,,,Yes,,y
WHO AMR pipeline analysis,Nov-21,LMN-201,Non-traditional,Bacteriophages and phage-derived enzymes,"Phage endolysin and three toxin-binding proteins (5D, E3, and 7F)s",C. difficile infections,Oral,Phase I,Lumen Bioscience,Clostridioides difficile,Clostridioides difficile,,,,Yes,,y
WHO AMR pipeline analysis,Nov-21,MET-2,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,Recurring C. difficile infections,Oral,Phase I,NuBiyota/ Takeda,Clostridioides difficile,Clostridioides difficile,,,,Yes,,y
WHO AMR pipeline analysis,Nov-21,MGB-BP-3,Antibiotics,,DNA minor groove binder (distamycin),C. difficile-associated diarrhea,"Oral, Not absorbed",Phase II,MGB Biopharma Ltd.,Clostridioides difficile,Clostridioides difficile,,,Yes,Yes,,y
WHO AMR pipeline analysis,Nov-21,RBX2660,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,C. difficile,Enema,Phase III,Ferring Pharmaceuticals,Clostridioides difficile,Clostridioides difficile,,,,Yes,,y
WHO AMR pipeline analysis,Nov-21,RBX7455,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,Recurring C. difficile infections,Oral,Phase I,Ferring (Rebiotix),Clostridioides difficile,Clostridioides difficile,,,,Yes,,y
WHO AMR pipeline analysis,Nov-21,Ridinilazole,Antibiotics,,Bis-benzimidazole,C. difficile infections,"Oral, Not absorbed",Phase III,Summit Therapeutics Inc.,Clostridioides difficile,Clostridioides difficile,,,Yes,Yes,,y
WHO AMR pipeline analysis,Nov-21,SER-109,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,C. difficile infections,Oral,Phase III,Seres Theraputics,Clostridioides difficile,Clostridioides difficile,,,,Yes,,y
WHO AMR pipeline analysis,Nov-21,SYN-004,Non-traditional,Microbiome-modulating agents,Antibiotic inactivator,C. difficile infections,Oral,Phase II,Synthetic Biologics,Clostridioides difficile,Clostridioides difficile,,,,Yes,,y
WHO AMR pipeline analysis,Nov-21,VE303,Non-traditional,Microbiome-modulating agents,Live biotherapeutic product,Recurring C. difficile infections,Oral,Phase II,Vedanta Biosciences,Clostridioides difficile,Clostridioides difficile,,,,Yes,,y
